PDCD1 and breast cancer: In recent years, incorporating immune checkpoint inhibitors (ICIs) that target programmed cell death 1 (PD-1) with its ligand PD-L1 has emerged as a promising neoadjuvant treatment strategy in early-stage solid tumors, such as breast cancer, lung cancer, and ESCC [7–9].